Research Peptide Spotlight: Calgri (Cagrilintide) is here! The long acting amylin analog that's blowing up in metabolic research. This powerhouse mimics your body's natural satiety hormone, helping dial down appetite and support Trial Scorecard: REDEFINE 1 and 2 In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Novo Nordisk's Cagrilintide shows promising weight loss in REDEFINE 1 sub analysis, unveiled at EASD 2025 Pharmacally VisualAbstract: Combined cagrilintide and semaglutide for weight management well tolerated in early clinical trials 2 Minute Medicine